Literature DB >> 12186895

Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function.

Mohammad A Khan1, Hirofumi Akari, Sandra Kao, Claudia Aberham, David Davis, Alicia Buckler-White, Klaus Strebel.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) Vif protein is specifically packaged into virus particles through an interaction with viral genomic RNA in which it associates with the viral nucleoprotein complex. We now demonstrate for the first time that virus-associated Vif is subject to proteolytic processing by the viral protease (Pr). Pr-dependent processing of Vif was observed both in vivo and in vitro. In vivo processing of Vif was cell type independent and evident by the appearance of a 7-kDa processing product, which was restricted to cell-free virus preparations. Processing of Vif required an active viral Pr and was sensitive to Pr inhibitors such as ritonavir. The processing site in Vif was characterized both in vivo and in vitro and mapped to Ala(150). Interestingly, the Vif processing site is located in a domain that is highly conserved among HIV-1, HIV-2, and simian immunodeficiency virus Vif isolates. Mutations at or near the processing site did not affect protein stability or packaging efficiency but had dramatic effects on Vif processing. In general, mutations that markedly increased or decreased the sensitivity of Vif to proteolytic processing severely impaired or completely abolished Vif function. In contrast, mutations at the same site that had little or no effect on processing efficiency also did not influence Vif function. None of the mutants affected the ability of the virus to replicate in permissive cell lines. Our data suggest that mutations in Vif that cause a profound change in the sensitivity to Pr-dependent processing also severely impaired Vif function, suggesting that intravirion processing of Vif is important for the production of infectious viruses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186895      PMCID: PMC136454          DOI: 10.1128/jvi.76.18.9112-9123.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in 'non-permissive' T lymphoid cells stably infected with selectable HIV-1.

Authors:  C Ochsenbauer; T Wilk; V Bosch
Journal:  J Gen Virol       Date:  1997-03       Impact factor: 3.891

3.  Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells.

Authors:  M Bouyac; F Rey; M Nascimbeni; M Courcoul; J Sire; D Blanc; F Clavel; R Vigne; B Spire
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells.

Authors:  J H Simon; R A Fouchier; T E Southerling; C B Guerra; C K Grant; M H Malim
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission.

Authors:  J H Simon; D L Miller; R A Fouchier; M A Soares; K W Peden; M H Malim
Journal:  EMBO J       Date:  1998-08-10       Impact factor: 11.598

6.  Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor.

Authors:  M Bouyac; M Courcoul; G Bertoia; Y Baudat; D Gabuzda; D Blanc; N Chazal; P Boulanger; J Sire; R Vigne; B Spire
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

7.  The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.

Authors:  J H Simon; M H Malim
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  The redox state of cysteines in human immunodeficiency virus type 1 Vif in infected cells and in virions.

Authors:  P Sova; W Chao; D J Volsky
Journal:  Biochem Biophys Res Commun       Date:  1997-11-17       Impact factor: 3.575

9.  Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins.

Authors:  R A Fouchier; J H Simon; A B Jaffe; M H Malim
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

10.  Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps.

Authors:  M Courcoul; C Patience; F Rey; D Blanc; A Harmache; J Sire; R Vigne; B Spire
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  12 in total

1.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

2.  Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus.

Authors:  Sarah M Rue; Jason W Roos; Patrick M Tarwater; Janice E Clements; Sheila A Barber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 3.  Advances in the structural understanding of Vif proteins.

Authors:  Pierre Barraud; Jean-Christophe Paillart; Roland Marquet; Carine Tisné
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

4.  Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.

Authors:  Dona Sleiman; Serena Bernacchi; Santiago Xavier Guerrero; Franck Brachet; Valéry Larue; Jean-Christophe Paillart; Carine Tisne
Journal:  RNA Biol       Date:  2014-07-22       Impact factor: 4.652

Review 5.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

Review 6.  Protein intrinsic disorder as a flexible armor and a weapon of HIV-1.

Authors:  Bin Xue; Marcin J Mizianty; Lukasz Kurgan; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

7.  Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.

Authors:  Robert C Walker; Mohammad A Khan; Sandra Kao; Ritu Goila-Gaur; Eri Miyagi; Klaus Strebel
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

8.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 9.  Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Authors:  Simon Henriet; Gaëlle Mercenne; Serena Bernacchi; Jean-Christophe Paillart; Roland Marquet
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

10.  Ring finger protein ZIN interacts with human immunodeficiency virus type 1 Vif.

Authors:  Feng Feng; Adam Davis; Julie-Anne Lake; Jill Carr; Wei Xia; Christopher Burrell; Peng Li
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.